Presagen awarded best research paper for 2022 by RBMO for its international clinical study on the Life Whisperer Viability AI
AI healthcare company Presagen is the winner of Reproductive Biomedicine Online (RMBO’s) annual Robert G. Edwards Prize Paper Award for the best paper published in 2022. The research paper describes how Life Whisperer’s Viability Artificial Intelligence (AI), by assessing images of embryos, is effective in improving the ranking and selection of viable embryos. The AI scores correlate with morphological and genetic features that are known to represent a good quality embryo. Life Whisperer is commercially available is 47 countries globally.
The international clinical study was conducted with clinics globally, including Ovation Fertility (USA), Texas Fertility Centre (USA), Alpha IVF and Women’s Specialists (Malaysia), Safe Fertility (Thailand), ORM Fertility (USA), Flinders Fertility (Australia), Midwest Fertility Specialists (USA), and IVF-Spain (Spain).
The research study was led by Dr Sonya Diakiw (first author), Presagen’s Chief Medical Science Officer, Dr Jonathan Hall, Presagen’s Co-founder and Chief Scientific Officer, and Dr Michelle Perugini (senior author) Presagen’s CEO and Co-Founder.
The winning paper receives a €1000 Euro prize, a complimentary ScienceDirect Ambassador Account (sponsored by the Publisher, Elsevier), award certificates, and an invitation to give a presentation related to the wining paper at Fertility 2024.
Paper title: “An artificial intelligence model correlated with morphological and genetic features of blastocyst quality improves ranking of viable embryos”
Authors: Sonya Diakiw, Jonathan M.M. Hall, Matthew VerMilyea, Adelle Y.X. Lim, Wiwat Quangkananurug, Sujin Chanchamroen, Brandon Bankowski, Rebecca Stones, Ashleigh Storr, Andrew Miller, Glen Adaniya, RaeAnne van Tol, Roberta Hanson, Jon Aizpurua, Lydia Giardini, Adrian Johnston, Tuc Van Nguyen, Milad A. Dakka, Don Perugini, Dr Michelle Perugini
Link to RBMO’s announcement: https://www.linkedin.com/pulse/rbmo-insights-issue-14-june-2023-reproductive-biomedicine-online%3FtrackingId=YiW2v6S0RT64YgVFmONhnA%253D%253D/?trackingId=YiW2v6S0RT64YgVFmONhnA%3D%3D
Click here to download the paper:
Go to the publication web site: https://www.rbmojournal.com/article/S1472-6483(22)00523-5/fulltext
Life Whisperer
Life Whisperer is a world-leader in the application of AI in IVF. The Life Whisperer Viability and Genetics AI-based embryo assessment tools are the first to be commercialized in a series of applications that encompass the complete IVF journey. Life Whisperer aims to improve IVF success rates at every point and, as a result, reduce time-to-pregnancy, making IVF more affordable and accessible to patients globally. Life Whisperer is being used in IVF clinics around the world.
Presagen
Presagen is an AI healthcare company that is changing the way clinics, patients, and medical data from around the world are connected through AI. Its platform, The Social Network for Healthcare, connects clinics and patients globally, and enables collaboration and data sharing to create scalable AI healthcare products that are affordable and accessible for all. The decentralized network democratizes the creation of AI products, promotes collaboration through incentives, and protects data privacy and ownership. With a focus on improving Women’s Health outcomes globally, Presagen’s first product, Life Whisperer, is being used by IVF clinics globally to improve pregnancy outcomes for couples struggling with fertility. With a vision of creating the largest network of clinics, patients, and medical data from around the world, Presagen is driving the future of AI Enhanced Healthcare.
